Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | GRK5 | P34947 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28301620 | 0.83 | SCN9A (0.45) | HCRTR1HCRTR2SCN9AEGFRKAT6A | |
| SCHEMBL4542718 | 0.83 | PRKCI (0.53) | HCRTR1HCRTR2SCN9AKAT6A | |
| SCHEMBL7693404 | 0.81 | TAAR1 (0.46) | HCRTR1HCRTR2SCN9AEGFRKAT6A | |
| SCHEMBL7855710 | 0.81 | HCRTR1 (0.43) | HCRTR1HCRTR2SCN9AEGFRKAT6A | |
| SCHEMBL8233552 | 0.79 | METAP2 (0.44) | — | |
| SCHEMBL10151028 | 0.77 | SCN9A (0.51) | IDO1SCN9AEGFRKAT6AGRK5 | |
| SCHEMBL30989356 | 0.77 | SCN9A (0.51) | IDO1SCN9AEGFRKAT6AGRK5 | |
| SCHEMBL5322690 | 0.75 | RAB9A (0.54) | IDO1SCN9AEGFRKAT6A | |
| SCHEMBL4536161 | 0.75 | TP53 (0.49) | KAT6A | |
| SCHEMBL10272458 | 0.75 | SREBF2 (0.48) | SCN9AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | IDO1 940/4885HCRTR1 3155/4885HCRTR2 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.